{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:26:25Z","timestamp":1792931185523,"version":"4.5.0"},"reference-count":23,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A head\u2010to\u2010head comparison between enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) revealed similar survival benefits for castration\u2010resistant prostate cancer (CRPC) in the ENABLE study for PCa. Considering that a dose reduction of ENZ and ABI has demonstrated sufficient inhibitory ability of androgen receptor (AR) signaling, we analyzed the efficacy of modified doses of these agents in the ENABLE study for PCa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This investigator\u2010initiated, multicenter, randomized controlled trial that was conducted in Japan analyzed the prespecified survival endpoints, prostate\u2010specific antigen (PSA) response rate (\u2009\u226550% decline from baseline), and safety profile in patients treated with modified doses (ENZ\u2009\u2264\u2009120\u2009mg\/day, ABI\u2009\u2264\u2009750\u2009mg\/day) compared with those treated with a standard dose (ENZ 160\u2009mg\/day, ABI 1000\u2009mg\/day) as a starting dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 92 patients in each arm were treated and analyzed; 16 patients were treated with a modified dose in both the ENZ and ABI arms, respectively. Moreover, 32 patients treated with modified doses showed a significantly better time to PSA progression (TTPP) and overall survival (OS) compared with the 152 patients treated with a standard dose (HR 0.47, 95%CI 0.27\u20130.83,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0379, and HR 0.35, 95%CI 0.19\u20130.63,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0162). Despite a significantly longer TTPP in the modified ABI group than in the standard ABI group (HR 0.29, 95%CI 0.14\u20130.62,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0248), no significant difference was observed in the TTPP between the modified and standard ENZ groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.5366). Furthermore, similar adverse event rates and grades were observed in each treatment dose group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The modified doses of ABI showed better TTPP than the standard dose of ABI and may be a potential treatment option for CRPC patients; however, its mechanism is still unclear, although its ability to suppress AR signaling is equivalent to that of a standard dose.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pros.24796","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T07:14:12Z","timestamp":1726816452000},"page":"21-29","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Dose modification in enzalutamide and abiraterone plus prednisolone for castration\u2010resistant prostate cancer: A subanalysis from the ENABLE study for PCa"],"prefix":"10.1002","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9242-7877","authenticated-orcid":false,"given":"Nobumichi","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Urology and Department of Prostate Brachytherapy Nara Medical University Kashihara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8480-9100","authenticated-orcid":false,"given":"Kouji","family":"Izumi","sequence":"additional","affiliation":[{"name":"Department of Integrative Cancer Therapy and Urology Kanazawa University Graduate School of Medical Science Kanazawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Nakai","sequence":"additional","affiliation":[{"name":"Department of Urology and Department of Prostate Brachytherapy Nara Medical University Kashihara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Shima","sequence":"additional","affiliation":[{"name":"Department of Urology Toyama Prefectural Central Hospital Toyama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Integrative Cancer Therapy and Urology Kanazawa University Graduate School of Medical Science Kanazawa Japan"},{"name":"Department of Urology Fukui\u2010ken Saiseikai Hospital Fukui Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Mita","sequence":"additional","affiliation":[{"name":"Department of Urology Hiroshima City North Medical Center Asa Citizens Hospital Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Kamiyama","sequence":"additional","affiliation":[{"name":"Department of Urology University of Yamanashi Chuo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Urology Shobara Red Cross Hospital Shobara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Hoshi","sequence":"additional","affiliation":[{"name":"Department of Urology Fukushima Medical University Fukushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Okamura","sequence":"additional","affiliation":[{"name":"Department of Urology Anjo Kosei Hospital Anjo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Yoshio","sequence":"additional","affiliation":[{"name":"Mie University Graduate School of Medicine Nephro\u2010Urologic Surgery and Andrology Tsu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Enokida","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medical and Dental Sciences Kagoshima University Kagoshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ippei","family":"Chikazawa","sequence":"additional","affiliation":[{"name":"Department of Urology Kanazawa Medical University Kahoku Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2257-3892","authenticated-orcid":false,"given":"Noriyasu","family":"Kawai","sequence":"additional","affiliation":[{"name":"Department of Nephro\u2010urology Nagoya City University Graduate School of Medical Sciences Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-4642","authenticated-orcid":false,"given":"Kohei","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine Sapporo Medical University Sapporo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Fukagai","sequence":"additional","affiliation":[{"name":"Department of Urology Showa University School of Medicine Shinagawa\u2010ku Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Shigehara","sequence":"additional","affiliation":[{"name":"Department of Integrative Cancer Therapy and Urology Kanazawa University Graduate School of Medical Science Kanazawa Japan"},{"name":"Department of Urology Ishikawa Prefectural Central Hospital Kanazawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuko","family":"Takahara","sequence":"additional","affiliation":[{"name":"Innovative Clinical Research Center Kanazawa University Kanazawa Japan"},{"name":"Medical Research Support Center University of Fukui Hospital Fukui Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5643-2182","authenticated-orcid":false,"given":"Atsushi","family":"Mizokami","sequence":"additional","affiliation":[{"name":"Department of Integrative Cancer Therapy and Urology Kanazawa University Graduate School of Medical Science Kanazawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,20]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyv002"},{"key":"e_1_2_10_4_1","doi-asserted-by":"crossref","unstructured":"Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate cancer trialists' collaborative group Lancet.2000;355:1491\u20131498.","DOI":"10.1016\/S0140-6736(00)02163-2"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10647"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4487"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405095"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71205-7"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-011-0349-5"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2022.04.016"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60172-9"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12496"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.1684"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24243"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24082"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201202367"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.270"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23799"},{"key":"e_1_2_10_21_1","first-page":"5201","article-title":"Ethinylestradiol improves prostate\u2010specific antigen levels in pretreated castration\u2010resistant prostate cancer patients","volume":"30","author":"Izumi K","year":"2010","journal-title":"Anticancer Res"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14194"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15568"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030508"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.24796","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T06:45:39Z","timestamp":1733121939000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.24796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,20]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1002\/pros.24796"],"URL":"https:\/\/doi.org\/10.1002\/pros.24796","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,20]]},"assertion":[{"value":"2024-06-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}